(Q36054268)

11 August 2017

1 reference

title

Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap? (English)

1 reference

11 August 2017

anti-retroviral agent

0 references

0 references

Giulia Marchetti

1

0 references

Andrea Gori

series ordinal

3

object named as

Andrea Gori

1 reference

11 August 2017

Fabio Franzetti

2

1 reference

PubMed ID

15731201

11 August 2017

language of work or name

English

0 references

publication date

24 February 2005

1 reference

Journal of Antimicrobial Chemotherapy

11 August 2017

1 reference

11 August 2017

55

1 reference

11 August 2017

401-409

1 reference

11 August 2017

4

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

11 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Immune Reconstitution Strategies in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Immune restoration with antiretroviral therapies: implications for clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Immunosuppressive drugs as an adjuvant to HIV treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Immune therapy: non-highly active antiretroviral therapy management of human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Restoration of the immune system with anti-retroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

CD4 cell counts at the third month of HAART may predict clinical failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

T-cell regeneration: all repertoires are not created equal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Control of homeostasis of CD8+ memory T cells by opposing cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

T cell receptor excision circles as markers for recent thymic emigrants: basic aspects, technical approach, and guidelines for interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Interleukin-7: from bench to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

IL-2, regulatory T cells, and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKH557

21 January 2018

Identifiers

DOI

10.1093/JAC/DKH557

1 reference

release_5bvrsactinhrboqgctelfjgtou

11 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5bvrsactinhrboqgctelfjgtou

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15731201

1 reference

PubMed ID

15731201